Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway

Xanthine oxidase (XO) is an important source of reactive oxygen species. This study investigated whether XO inhibition exerts renoprotective effects by inhibiting vascular endothelial growth factor (VEGF) and NADPH oxidase (NOX) in diabetic kidney disease (DKD). Febuxostat (5 mg/kg) was administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Keum-Jin, Choi, Won Jung, Chang, Yoon-Kyung, Park, Cheol Whee, Kim, Suk Young, Hong, Yu Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961241/
https://www.ncbi.nlm.nih.gov/pubmed/36835220
http://dx.doi.org/10.3390/ijms24043807
_version_ 1784895706033553408
author Yang, Keum-Jin
Choi, Won Jung
Chang, Yoon-Kyung
Park, Cheol Whee
Kim, Suk Young
Hong, Yu Ah
author_facet Yang, Keum-Jin
Choi, Won Jung
Chang, Yoon-Kyung
Park, Cheol Whee
Kim, Suk Young
Hong, Yu Ah
author_sort Yang, Keum-Jin
collection PubMed
description Xanthine oxidase (XO) is an important source of reactive oxygen species. This study investigated whether XO inhibition exerts renoprotective effects by inhibiting vascular endothelial growth factor (VEGF) and NADPH oxidase (NOX) in diabetic kidney disease (DKD). Febuxostat (5 mg/kg) was administered to streptozotocin (STZ)-treated 8-week-old male C57BL/6 mice via intraperitoneal injection for 8 weeks. The cytoprotective effects, its mechanism of XO inhibition, and usage of high-glucose (HG)-treated cultured human glomerular endothelial cells (GECs) were also investigated. Serum cystatin C, urine albumin/creatinine ratio, and mesangial area expansion were significantly improved in febuxostat-treated DKD mice. Febuxostat reduced serum uric acid, kidney XO levels, and xanthine dehydrogenase levels. Febuxostat suppressed the expression of VEGF mRNA, VEGF receptor (VEGFR)1 and VEGFR3, NOX1, NOX2, and NOX4, and mRNA levels of their catalytic subunits. Febuxostat caused downregulation of Akt phosphorylation, followed by the enhancement of dephosphorylation of transcription factor forkhead box O3a (FoxO3a) and the activation of endothelial nitric oxide synthase (eNOS). In an in vitro study, the antioxidant effects of febuxostat were abolished by a blockade of VEGFR1 or VEGFR3 via NOX-FoxO3a-eNOS signaling in HG-treated cultured human GECs. XO inhibition attenuated DKD by ameliorating oxidative stress through the inhibition of the VEGF/VEGFR axis. This was associated with NOX-FoxO3a-eNOS signaling.
format Online
Article
Text
id pubmed-9961241
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99612412023-02-26 Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway Yang, Keum-Jin Choi, Won Jung Chang, Yoon-Kyung Park, Cheol Whee Kim, Suk Young Hong, Yu Ah Int J Mol Sci Article Xanthine oxidase (XO) is an important source of reactive oxygen species. This study investigated whether XO inhibition exerts renoprotective effects by inhibiting vascular endothelial growth factor (VEGF) and NADPH oxidase (NOX) in diabetic kidney disease (DKD). Febuxostat (5 mg/kg) was administered to streptozotocin (STZ)-treated 8-week-old male C57BL/6 mice via intraperitoneal injection for 8 weeks. The cytoprotective effects, its mechanism of XO inhibition, and usage of high-glucose (HG)-treated cultured human glomerular endothelial cells (GECs) were also investigated. Serum cystatin C, urine albumin/creatinine ratio, and mesangial area expansion were significantly improved in febuxostat-treated DKD mice. Febuxostat reduced serum uric acid, kidney XO levels, and xanthine dehydrogenase levels. Febuxostat suppressed the expression of VEGF mRNA, VEGF receptor (VEGFR)1 and VEGFR3, NOX1, NOX2, and NOX4, and mRNA levels of their catalytic subunits. Febuxostat caused downregulation of Akt phosphorylation, followed by the enhancement of dephosphorylation of transcription factor forkhead box O3a (FoxO3a) and the activation of endothelial nitric oxide synthase (eNOS). In an in vitro study, the antioxidant effects of febuxostat were abolished by a blockade of VEGFR1 or VEGFR3 via NOX-FoxO3a-eNOS signaling in HG-treated cultured human GECs. XO inhibition attenuated DKD by ameliorating oxidative stress through the inhibition of the VEGF/VEGFR axis. This was associated with NOX-FoxO3a-eNOS signaling. MDPI 2023-02-14 /pmc/articles/PMC9961241/ /pubmed/36835220 http://dx.doi.org/10.3390/ijms24043807 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yang, Keum-Jin
Choi, Won Jung
Chang, Yoon-Kyung
Park, Cheol Whee
Kim, Suk Young
Hong, Yu Ah
Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway
title Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway
title_full Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway
title_fullStr Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway
title_full_unstemmed Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway
title_short Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway
title_sort inhibition of xanthine oxidase protects against diabetic kidney disease through the amelioration of oxidative stress via vegf/vegfr axis and nox-foxo3a-enos signaling pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961241/
https://www.ncbi.nlm.nih.gov/pubmed/36835220
http://dx.doi.org/10.3390/ijms24043807
work_keys_str_mv AT yangkeumjin inhibitionofxanthineoxidaseprotectsagainstdiabetickidneydiseasethroughtheameliorationofoxidativestressviavegfvegfraxisandnoxfoxo3aenossignalingpathway
AT choiwonjung inhibitionofxanthineoxidaseprotectsagainstdiabetickidneydiseasethroughtheameliorationofoxidativestressviavegfvegfraxisandnoxfoxo3aenossignalingpathway
AT changyoonkyung inhibitionofxanthineoxidaseprotectsagainstdiabetickidneydiseasethroughtheameliorationofoxidativestressviavegfvegfraxisandnoxfoxo3aenossignalingpathway
AT parkcheolwhee inhibitionofxanthineoxidaseprotectsagainstdiabetickidneydiseasethroughtheameliorationofoxidativestressviavegfvegfraxisandnoxfoxo3aenossignalingpathway
AT kimsukyoung inhibitionofxanthineoxidaseprotectsagainstdiabetickidneydiseasethroughtheameliorationofoxidativestressviavegfvegfraxisandnoxfoxo3aenossignalingpathway
AT hongyuah inhibitionofxanthineoxidaseprotectsagainstdiabetickidneydiseasethroughtheameliorationofoxidativestressviavegfvegfraxisandnoxfoxo3aenossignalingpathway